基孔肯雅病毒样颗粒疫苗单剂可诱导跨谱系及跨甲病毒中和
本研究基于2期临床试验受试者血清,评估单剂基孔肯雅病毒样颗粒疫苗VIMKUNYA对多种基孔肯雅病毒株及相关致关节炎甲病毒的中和活性。结果显示,单剂接种可诱导针对多个基孔肯雅病毒谱系的交叉中和抗体,并对数种相关致关节炎甲病毒产生可测的交叉中和活性;既往接种过甲病毒疫苗者的免疫应答与未暴露者相当。
要点
- 单剂CHIKV VLP疫苗可诱导针对多个CHIKV谱系的交叉中和抗体。
- 单剂接种后对相关致关节炎甲病毒产生可测的交叉中和活性。
- 既往甲病毒疫苗接种史不影响单剂CHIKV VLP疫苗的免疫应答。
核心结论
- 单剂CHIKV VLP疫苗具有广谱免疫原性,支持其适用于包括既往甲病毒暴露者在内的多样化人群。
研究设计与样本
- 基于2期临床试验受试者血清的分析,评估单剂CHIKV VLP疫苗后的中和活性。
主要发现
- 单剂接种诱导针对多个CHIKV谱系的交叉中和抗体。
- 单剂接种后对数种相关致关节炎甲病毒产生可测的交叉中和活性。
- 既往甲病毒疫苗接种者的免疫应答与甲病毒未暴露者相当。
关键数值与推荐
- VIMKUNYA™已在美国、欧盟/欧洲经济区、英国和瑞士获批使用。
临床怎么用
- 单剂CHIKV VLP疫苗可用于诱导针对多样CHIKV株和相关致关节炎甲病毒的交叉中和抗体。
- 既往甲病毒疫苗接种史不构成单剂CHIKV VLP疫苗接种的障碍。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chikungunya virus (CHIKV) is a mosquito-borne virus that has spread widely and infected millions of people. CHIKV can cause both acute and chronic polyarthralgia that can be debilitating. The CHIKV virus-like particle (VLP) vaccine, VIMKUNYA™, is approved for use in the US, EU/EEA, UK, and Switzerland. METHODS: The aim of this study was two-fold: 1) determine if a single dose of CHIKV VLP vaccine generates cross-neutralizing antibodies against diverse CHIKV strains representing major viral lineages, as well as other arthritogenic alphaviruses, and 2) determine if previous alphavirus vaccination alters the ability to generate cross-neutralizing antibodies after CHIKV VLP vaccination. In this analysis, sera from participants enrolled in a phase 2 study were assessed for neutralizing activity against multiple CHIKV strains and related alphaviruses. RESULTS: A single vaccination with CHIKV VLP vaccine induced cross-neutralizing antibodies against multiple lineages of CHIKV and generated measurable cross-neutralizing activity against several related arthritogenic alphaviruses. Importantly, individuals with prior history of alphavirus vaccination exhibited immune responses comparable to alphavirus-naïve participants, indicating that earlier exposure did not hinder the ability to mount a strong CHIKV-specific or cross-reactive antibody response. CONCLUSIONS: These results highlight the broad immunogenic potential of CHIKV VLP vaccine and support its suitability across diverse populations, including individuals with prior alphavirus exposure, as previous vaccination did not diminish the ability to generate robust CHIKV-specific or cross-neutralizing antibody responses against CHIKV and other arthritogenic alphaviruses.
引用
- Gardner CL, Brown NN, Brown JL, et al. Chikungunya virus virus-like particle vaccine (VIMKUNYA) elicits cross-neutralization across CHIKV lineages and against other alphaviruses after just one dose. Vaccine. 2026. PMID: 42424825. doi:10.1016/j.vaccine.2026.128892
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。